In vitro advanced antimycobacterial screening of isoniazid-related hydrazones, hydrazides and cyanoboranes: Part 14

Bioorganic and Medicinal Chemistry Letters

Volumn 15, Issue 10, 2005, Pages 2509-2513

  Maccari, Rosanna ^a   Ottanà, Rosaria ^a   Vigorita, Maria Gabriella ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Antimycobacterial activity; Isoniazid related compounds; Structure activity relationships

Indexed keywords

BORANE DERIVATIVE; HYDRAZIDE DERIVATIVE; HYDRAZONE DERIVATIVE; ISONIAZID DERIVATIVE;

ANTIMICROBIAL ACTIVITY; ARTICLE; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG SCREENING; DRUG SYNTHESIS; IC 50; IN VITRO STUDY; LIPOPHILICITY; MACROPHAGE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

EID: 18144385120     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.03.065     Document Type: Article

References (38)

1. F.M. Collins Clin. Microb. Rev. 2 1989 360
2. N.M.H. Graham, N. Galai, K.E. Nelson, J. Astemborski, M. Bonds, R.T. Rizzo, L. Sheeley, and D. Vlahov Arch. Intern. Med. 156 1996 889
3. N.A. Halsey, J.S. Coberly, J. Desormeaux, P. Losikoff, J. Atkinson, L.H. Moulton, M. Contave, M. Johnson, H. Davis, L. Geiter, E. Johnson, R. Huebner, R. Boulos, and R.E. Chaisson Lancet 351 1998 786
4. L.A. Basso, and J.S. Blanchard Adv. Exp. Med. Biol. 456 1998 115
5. I. Bastian, and R. Colebunders Drugs 58 1999 633
6. TAACF Web Site: www.taacf.org
7. E.E. Telzak, K. Sepkowitz, P. Alpert, S. Mannheimer, F. Medard, W. El-Sadr, S. Blum, A. Gagliardi, N. Salomon, and G.N. Turett Engl. J. Med. 333 1995 907
8. WHO Web Site: www.who.int/en/
9. Sizemore, C. F.; Fauci, A. S. In NIAID Web Site: www2.niaid.nih.gov/ newsroom/releases/tbday2004.htm
10. G.L. Mandell, and W.A. Petri Jr. Goodman and Gilman's The Pharmacological Basis of Therapeutics 1996 Mc Graw-Hill New York pp 1155-1174
11. P. Sensi, and G. Gialdroni Grassi M.E. Wolff Burger's Medicinal Chemistry and Drug Discovery 1996 John Wiley & Sons New York 575 635
12. A. Jindani, A.J. Nunn, and D.A. Enarson Lancet 364 2004 1244
13. R. Maccari, R. Ottanà, B. Bottari, E. Rotondo, and M.G. Vigorita Bioorg. Med. Chem. Lett. 14 2004 5731
14. R. Maccari, R. Ottanà, F. Monforte, and M.G. Vigorita Antimicrob. Agents Chemother. 46 2002 294
15. B. Bottari, R. Maccari, F. Monforte, R. Ottanà, M.G. Vigorita, G. Bruno, F. Nicolò, A. Rotondo, and E. Rotondo Bioorg. Med. Chem. 9 2001 2203
16. B. Bottari, R. Maccari, F. Monforte, R. Ottanà, E. Rotondo, and M.G. Vigorita Bioorg. Med. Chem. Lett. 11 2001 301
17. B. Bottari, R. Maccari, F. Monforte, R. Ottanà, E. Rotondo, and M.G. Vigorita Bioorg. Med. Chem. Lett. 10 2000 657
18. M.G. Vigorita, R. Ottanà, C. Zappalà, R. Maccari, F.C. Pizzimenti, and G. Gabbrielli Il Farmaco 50 1995 783
19. M.G. Vigorita, R. Ottanà, C. Zappalà, R. Maccari, F.C. Pizzimenti, and G. Gabbrielli Il Farmaco 49 1994 775
20. M.G. Vigorita, M. Basile, C. Zappalà, G. Gabbrielli, and F. Pizzimenti Il Farmaco 47 1992 893
21. R. Ottanà, R. Maccari, and M.G. Vigorita J. Chem. Res. (S) 12 1994 496
22. R. Ottanà, R. Maccari, M.G. Vigorita, and E. Rotondo J. Chem. Res. 9 (S), 550 (M) 1998 2532
23. 1H NMR monitoring did not reveal any alteration
24. E. Tomlison J. Chromat. 113 1975 1
25. G.L. Biagi, M. Recanatini, A.M. Barbero, M.C. Guerra, A. Sapone, P.A. Brea, and M.C. Pietrogande C. Silipo A. Vittoria Chromatographic Rm values as lipophilicity index in QSAR: Rational Approach to the Design of Bioactive Compounds 1991 Elsevier Science Amsterdam 83 90
26. 254 - Merck)
27. P.S. Skinner, S.K. Furney, M.R. Jacobs, G. Klopman, J.J. Ellner, and I.M. Orme Antimicrob. Agents Chemother. 38 1994 2557
28. N.A. Carlone, A.M. Cuffini, V. Tullio, and G. Cavallo J. Chemother. 3 1991 98
29. W.L. Hand, and N.L. King-Thompson Antimicrob. Agents Chemother. 34 1990 1189
30. M.G. Vigorita, R. Maccari, R. Ottanà, and F. Monforte Med. Chem. Res. 9 1999 306
31. MICs against a panel of SDR strains (i.e., each strain being resistant to a single anti-TB drug), typically an M. tuberculosis strains resistant to isoniazid (ATCC 35822), a strain resistant to rifampin (ATCC 35838) and one or more additional SDR strains, were determined using MABA
32. L.A. Collins, and S.G. Franzblau Antimicrob. Agents Chemother. 41 1997 1004
33. S.G. Franzblau, R.S. Witzig, J.C. McLaughlin, P. Torres, G. Madico, A. Hernandez, M.T. Degnan, M.B. Cook, V.K. Quenzer, R.M. Freguson, and R.H. Gilman J. Clin. Microb. 36 1998 362
34. The Minimum Bactericidal Concentration (MBC) was determined for M. tuberculosis H37Rv and for the appropriate drug-resistant strain by subculturing onto drug-free solid media and enumerating CFU after exposure in supplemented Middlebrook 7H9 media to drug concentrations equivalent to and higher than the previously determined MICs against the respective strains
35. A. Banerjee, E. Dubnau, A. Quemard, V. Balasubramanian, K.S. Um, T. Wilson, D. Collins, G. DeLisle, and W.R. Jacobs Science 263 1994 227
36. K. Johnsson, D.S. King, and P.G. Schultz J. Am. Chem. Soc. 117 1995 5009
37. A. Quemard, A. Dessen, M. Sugantino, W.R. Jacobs, J.C. Sacchettini, and J.S. Blanchard J. Am. Chem. Soc. 118 1996 1561
38. C.B. Inderlied, C.A. Kemper, and L.E.M. Bermudez Clin. Microb. Rev. 6 1993 266